RECRUITING Phase 2 ClinicalTrials.gov

FAPI PET Imaging in Nonischemic Cardiomyopathy

Sponsor: Peking Union Medical College Hospital • ClinicalTrials.gov ID: NCT07878338

Registry updated: 2026-10-16

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This study aims to evaluate the clinical value of \[¹⁸F\]AlF-NOTA-FAPI-04 PET/CT for the noninvasive assessment of myocardial fibroblast activation in patients with nonischemic cardiomyopathy. The study will investigate whether \[¹⁸F\]AlF-NOTA-FAPI-04 PET/CT can provide complementary information for disease phenotyping, assessment of treatment response, and prognostic risk stratification in nonischemic cardiomyopathy.

Interventions

[¹⁸F]AlF-NOTA-FAPI-04 (Drug)
An I.V. bolus injection of up to 10 millicurie (mCi) \[¹⁸F\]AlF-NOTA-FAPI-04 will be administered, followed by a PET/CT scan.

Eligibility criteria

Inclusion Criteria: 1. males or females: age 18-90 years 2. with a confirmed diagnosis of nonischemic cardiomyopathy by standard criteria 3. must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements Exclusion Criteria: 1. coronary atherosclerotic disease (CAD) according to electrocardiogram, coronary artery CTA, or coronary angiography 2. pregnancy or breastfeeding 3. severe claustrophobia 4. inability or refusal of consent 5. any condition deemed by the investigator to interfere with study results or increase participant risk

Conditions

Nonischemic Cardiomyopathy

Locations

Peking Union Medical College Hospital — Beijing, China

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment